{"transactions":[{"id":712034,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee stock option (right to buy)","published_at":"2026-07-09T20:11:06.000Z","date":"2026-07-07","kind":"grant","planned":false,"acquired":true,"shares":48285,"price":5.29,"value":255427.65,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option grant described in this Form 4 filing vests as to 25% of the original shares on July 7, 2027 and as to an additional 6.25% of the original shares each successive quarter and until July 7, 2030."}],"balance_after":48285,"derivative":{"exercise_price":5.29,"expiration_date":"2036-07-06","underlying":"Common Stock","underlying_shares":48285},"source":{"system":"sec-edgar","filing":"0001108205-26-000091","document":"wk-form4_1783627863.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000091/wk-form4_1783627863.xml","form_type":"4"}},{"id":831200,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Series B  Convertible Preferred Stock","published_at":"2026-03-23T20:03:25.000Z","date":"2026-03-20","kind":"exercise","planned":false,"acquired":false,"shares":50,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0001108205-26-000038","document":"wk-form4_1774296203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000038/wk-form4_1774296203.xml","form_type":"4"}},{"id":831199,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2026-03-23T20:03:25.000Z","date":"2026-03-20","kind":"exercise","planned":false,"acquired":true,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."}],"balance_after":77707,"source":{"system":"sec-edgar","filing":"0001108205-26-000038","document":"wk-form4_1774296203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000038/wk-form4_1774296203.xml","form_type":"4"}},{"id":835512,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Series C Warrant (right to buy)","published_at":"2026-03-18T20:21:39.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series C Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing on March 17, 2026."}],"balance_after":66666,"derivative":{"exercise_price":0.75,"expiration_date":"2027-07-08","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0001108205-26-000026","document":"wk-form4_1773865293.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000026/wk-form4_1773865293.xml","form_type":"4"}},{"id":835511,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Series B Warrant (right to buy)","published_at":"2026-03-18T20:21:39.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia (\"Initial Termination Date\"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the \"Exercise Price\"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia (\"Initial Termination Date\"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the \"Exercise Price\"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia (\"Initial Termination Date\"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the \"Exercise Price\"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days."}],"balance_after":66666,"derivative":{"exercise_price":0.75,"underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0001108205-26-000026","document":"wk-form4_1773865293.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000026/wk-form4_1773865293.xml","form_type":"4"}},{"id":835510,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Series A Warrant (right to buy)","published_at":"2026-03-18T20:21:39.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":66666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Series A Warrant became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series A Warrant) on March 17, 2026."}],"balance_after":66666,"derivative":{"exercise_price":0.75,"expiration_date":"2031-01-08","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0001108205-26-000026","document":"wk-form4_1773865293.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000026/wk-form4_1773865293.xml","form_type":"4"}},{"id":835509,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Series B  Convertible Preferred Stock","published_at":"2026-03-18T20:21:39.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":50,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026,  subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations  (as defined in the Certificate of Designations)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026,  subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations  (as defined in the Certificate of Designations)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026,  subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations  (as defined in the Certificate of Designations)."}],"balance_after":50,"derivative":{"underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0001108205-26-000026","document":"wk-form4_1773865293.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000026/wk-form4_1773865293.xml","form_type":"4"}},{"id":1137778,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee stock option (right to buy)","published_at":"2025-05-22T20:13:02.000Z","date":"2025-05-20","kind":"grant","planned":false,"acquired":true,"shares":135000,"price":3.13,"value":422550.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This option grant, as disclosed in Curis Inc.'s 2025 proxy statement, was approved by the Board of Directors of Curis, Inc. on January 28, 2025, contingent upon shareholder approval of Curis's Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if Amendment No. 1 to the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 20, 2025, at the 2025 annual meeting of shareholders, Curis's shareholders approved Amendment No. 1 to the Fifth Amended and Restated 2010 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option grant described in this Form 4 filing vests as to 25% of the original shares on January 28, 2026 and as to an additional 6.25% of the original shares each successive quarter and until January 28, 2029."}],"balance_after":135000,"derivative":{"exercise_price":3.13,"expiration_date":"2035-01-27","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001108205-25-000065","document":"wk-form4_1747944773.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820525000065/wk-form4_1747944773.xml","form_type":"4"}},{"id":1291029,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee stock option (right to buy)","published_at":"2025-01-30T21:11:25.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":3.13,"value":46950.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option grant described in this Form 4 filing vests as to 25% of the original shares on January 28, 2026 and as to an additional 6.25% of the original shares each successive quarter and until January 28, 2029."}],"balance_after":15000,"derivative":{"exercise_price":3.13,"expiration_date":"2035-01-27","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001108205-25-000018","document":"wk-form4_1738271478.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820525000018/wk-form4_1738271478.xml","form_type":"4"}},{"id":1504130,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee stock option (right to buy)","published_at":"2024-05-23T20:12:21.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":39000,"price":11.62,"value":453180.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This option grant, as disclosed in Curis Inc.'s 2024 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 19, 2024, contingent upon shareholder approval of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan to, among other things, increase the number of shares authorized for issuance thereunder and increase the per participant limit on the number of shares subject to awards that can be granted annually to participants in the plan; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 21, 2024, at the 2024 annual meeting of shareholders, Curis's shareholders approved the Fifth Amended and Restated 2010 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option grant described in this Form 4 filing vests as to 25% of the original shares on January 19, 2025 and as to an additional 6.25% of the original shares each successive quarter and until January 19, 2028."}],"balance_after":39000,"derivative":{"exercise_price":11.62,"expiration_date":"2034-01-18","underlying":"Common Stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001108205-24-000055","document":"wk-form4_1716495126.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000055/wk-form4_1716495126.xml","form_type":"4"}},{"id":2047767,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Employee stock option (right to buy)","published_at":"2023-01-24T21:10:35.000Z","date":"2023-01-20","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option grant described in this Form 4 filing vests as to 25% of the original shares on January 20, 2024 and as to an additional 6.25% of the original shares each successive quarter and until January 20, 2027."}],"balance_after":500000,"derivative":{"exercise_price":0.7,"expiration_date":"2033-01-19","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001108205-23-000011","document":"wf-form4_167459462169459.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820523000011/wf-form4_167459462169459.xml","form_type":"4"}},{"id":2244489,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-06-03T16:13:21.000Z","date":"2022-06-02","kind":"sale","acquired":false,"shares":1355,"price":0.06,"value":81.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person."}],"balance_after":75388,"source":{"system":"sec-edgar","filing":"0001457612-22-000075","document":"wf-form4_165428718048421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761222000075/wf-form4_165428718048421.xml","form_type":"4"}},{"id":2255163,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-05-26T16:11:58.000Z","date":"2022-05-26","kind":"sale","acquired":false,"shares":24407,"price":0.0765,"value":1867.1355,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.0765 to $0.0766, inclusive."}],"balance_after":76743,"source":{"system":"sec-edgar","filing":"0001457612-22-000060","document":"wf-form4_165359588823596.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761222000060/wf-form4_165359588823596.xml","form_type":"4"}},{"id":2304269,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-04-05T08:17:54.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":963,"price":1.25,"value":1203.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person."}],"balance_after":91775,"source":{"system":"sec-edgar","filing":"0001457612-22-000045","document":"wf-form4_164916106048565.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761222000045/wf-form4_164916106048565.xml","form_type":"4"}},{"id":2327188,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-17T16:11:12.000Z","date":"2022-03-15","kind":"grant","acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options are scheduled to vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date."}],"balance_after":112500,"derivative":{"exercise_price":1.11,"expiration_date":"2032-03-15","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001457612-22-000030","document":"wf-form4_164754782084656.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761222000030/wf-form4_164754782084656.xml","form_type":"4"}},{"id":2327187,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-03-17T16:11:12.000Z","date":"2022-03-16","kind":"sale","acquired":false,"shares":2873,"price":1.1,"value":3160.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person."}],"balance_after":92738,"source":{"system":"sec-edgar","filing":"0001457612-22-000030","document":"wf-form4_164754782084656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761222000030/wf-form4_164754782084656.xml","form_type":"4"}},{"id":2327186,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-03-17T16:11:12.000Z","date":"2022-03-15","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units that represent the contingent right to receive, at settlement, one share of common stock. The restricted stock units are scheduled to vest 25% on each of the first four anniversaries of the grant date."}],"balance_after":95611,"source":{"system":"sec-edgar","filing":"0001457612-22-000030","document":"wf-form4_164754782084656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761222000030/wf-form4_164754782084656.xml","form_type":"4"}},{"id":2330683,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-03-16T17:31:08.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":511,"price":2.23,"value":1139.53,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person."}],"balance_after":62486,"source":{"system":"sec-edgar","filing":"0001457612-22-000020","document":"wf-form5_164746625165852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761222000020/wf-form5_164746625165852.xml","form_type":"5"}},{"id":2330682,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-03-16T17:31:08.000Z","date":"2021-04-02","kind":"sale","acquired":false,"shares":925,"price":2.71,"value":2506.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person."}],"balance_after":62997,"source":{"system":"sec-edgar","filing":"0001457612-22-000020","document":"wf-form5_164746625165852.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761222000020/wf-form5_164746625165852.xml","form_type":"5"}},{"id":2782055,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2021-03-17T13:59:14.000Z","date":"2021-03-15","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents the right to receive, at settlement, one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting of these restricted stock units depends on the average closing price of a share of Genocea Biosciences, Inc.'s common stock over the sixty trading days immediately preceding December 31, 2023. The\"target\" number of restricted stock units is reported. Between 75% and 150% of the target number of units may vest on December 31, 2023, with the vesting percentage determined based on actual performance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Vesting of these restricted stock units depends on the average closing price of a share of Genocea Biosciences, Inc.'s common stock over the sixty trading days immediately preceding December 31, 2023. The\"target\" number of restricted stock units is reported. Between 75% and 150% of the target number of units may vest on December 31, 2023, with the vesting percentage determined based on actual performance."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001457612-21-000042","document":"wf-form4_161600393732739.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761221000042/wf-form4_161600393732739.xml","form_type":"4"}},{"id":2782054,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-17T13:59:14.000Z","date":"2021-03-15","kind":"grant","acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options are scheduled to vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date."}],"balance_after":112500,"derivative":{"exercise_price":3.01,"expiration_date":"2031-03-15","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001457612-21-000042","document":"wf-form4_161600393732739.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761221000042/wf-form4_161600393732739.xml","form_type":"4"}},{"id":2782053,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2021-03-17T13:59:14.000Z","date":"2021-03-15","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units that represent the contingent right to receive, at settlement, one share of common stock. The restricted stock units are scheduled to vest 25% on each of the first four anniversaries of the grant date."}],"balance_after":37500,"source":{"system":"sec-edgar","filing":"0001457612-21-000042","document":"wf-form4_161600393732739.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761221000042/wf-form4_161600393732739.xml","form_type":"4"}},{"id":3126928,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-02T16:19:09.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":24938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date."}],"balance_after":24938,"derivative":{"exercise_price":2.72,"expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":24938},"source":{"system":"sec-edgar","filing":"0001457612-20-000079","document":"wf-form4_159112913161265.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761220000079/wf-form4_159112913161265.xml","form_type":"4"}},{"id":3126927,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2020-06-02T16:19:09.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":6623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person under the Amended and Restated 2014 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest one-fourth (1/4) on each of the first four (4) anniversaries on the date of grant."}],"balance_after":6623,"source":{"system":"sec-edgar","filing":"0001457612-20-000079","document":"wf-form4_159112913161265.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761220000079/wf-form4_159112913161265.xml","form_type":"4"}},{"id":3181593,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-06T16:06:17.000Z","date":"2020-04-02","kind":"grant","acquired":true,"shares":46313,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date."}],"balance_after":46313,"derivative":{"exercise_price":1.66,"expiration_date":"2030-04-02","underlying":"Common Stock","underlying_shares":46313},"source":{"system":"sec-edgar","filing":"0001457612-20-000025","document":"wf-form4_158620355845940.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761220000025/wf-form4_158620355845940.xml","form_type":"4"}},{"id":3181592,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2020-04-06T16:06:17.000Z","date":"2020-04-02","kind":"grant","acquired":true,"shares":12299,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person under the Amended and Restated 2014 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest one-fourth (1/4) on each of the first four (4) anniversaries on the date of grant."}],"balance_after":12299,"source":{"system":"sec-edgar","filing":"0001457612-20-000025","document":"wf-form4_158620355845940.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761220000025/wf-form4_158620355845940.xml","form_type":"4"}},{"id":3606198,"issuer":{"id":12635,"kind":"organization","name":"GENOCEA BIOSCIENCES, INC.","symbol":"GNCA"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-07T15:10:53.000Z","date":"2019-03-05","kind":"grant","acquired":true,"shares":475000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option shall become exercisable as to 1/4th of the shares subject to the option on the first anniversary of the Grant Date and thereafter as to 1/36th of the shares on each subsequent monthly anniversary of the Grant Date (rounded down to the nearest whole share, except for the final vesting period, with respect to which all remaining shares will vest)"}],"balance_after":475000,"derivative":{"exercise_price":0.83,"expiration_date":"2029-03-05","underlying":"Common Stock","underlying_shares":475000},"source":{"system":"sec-edgar","filing":"0001457612-19-000034","document":"wf-form4_155198943936581.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1457612/000145761219000034/wf-form4_155198943936581.xml","form_type":"4"}},{"id":4004804,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-03-08T12:22:34.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":11062,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":44.51,"underlying":"Common Stock","underlying_shares":11062},"source":{"system":"sec-edgar","filing":"0001127602-18-010658","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760218010658/form4.xml","form_type":"4"}},{"id":4004803,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-03-08T12:22:34.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":7030,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":52.08,"underlying":"Common Stock","underlying_shares":7030},"source":{"system":"sec-edgar","filing":"0001127602-18-010658","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760218010658/form4.xml","form_type":"4"}},{"id":4004802,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2018-03-08T12:22:34.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":7273,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one Share of the issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7273},"source":{"system":"sec-edgar","filing":"0001127602-18-010658","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760218010658/form4.xml","form_type":"4"}},{"id":4004801,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2018-03-08T12:22:34.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":2780,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one Share of the issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2780},"source":{"system":"sec-edgar","filing":"0001127602-18-010658","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760218010658/form4.xml","form_type":"4"}},{"id":4004800,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2018-03-08T12:22:34.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":2791,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes shares subject to restricted stock units.  See also note 4."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the \"Merger Agreement\"), between the Company, Sanofi, a French soci?t? anonyme (the \"Parent\"), and Blink Acquisition Corp. (\"Merger Sub\"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\").  Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a \"Share\") was converted into the right to receive $105.00 in cash."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001127602-18-010658","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760218010658/form4.xml","form_type":"4"}},{"id":4013552,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2018-03-05T17:02:06.000Z","date":"2018-03-02","kind":"tax_withholding","acquired":false,"shares":105,"price":104.73,"value":10996.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":2791,"source":{"system":"sec-edgar","filing":"0001127602-18-010132","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760218010132/form4.xml","form_type":"4"}},{"id":4032859,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2018-02-26T17:13:17.000Z","date":"2018-02-22","kind":"tax_withholding","acquired":false,"shares":168,"price":104.3,"value":17522.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":2896,"source":{"system":"sec-edgar","filing":"0001127602-18-008447","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760218008447/form4.xml","form_type":"4"}},{"id":4054161,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2018-02-15T17:11:22.000Z","date":"2018-02-14","kind":"exercise","acquired":false,"shares":1390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."}],"balance_after":2780,"derivative":{"underlying":"Common Stock","underlying_shares":1390},"source":{"system":"sec-edgar","filing":"0001127602-18-006428","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760218006428/form4.xml","form_type":"4"}},{"id":4054160,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2018-02-15T17:11:22.000Z","date":"2018-02-14","kind":"tax_withholding","acquired":false,"shares":454,"price":103.52,"value":46998.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":3064,"source":{"system":"sec-edgar","filing":"0001127602-18-006428","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760218006428/form4.xml","form_type":"4"}},{"id":4054159,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2018-02-15T17:11:22.000Z","date":"2018-02-14","kind":"exercise","acquired":true,"shares":1390,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3518,"source":{"system":"sec-edgar","filing":"0001127602-18-006428","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760218006428/form4.xml","form_type":"4"}},{"id":4078425,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2018-02-02T17:18:25.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":7273,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on January 31, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on January 31, 2019."}],"balance_after":7273,"derivative":{"underlying":"Common Stock","underlying_shares":7273},"source":{"system":"sec-edgar","filing":"0001127602-18-003819","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760218003819/form4.xml","form_type":"4"}},{"id":4269929,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2017-06-29T17:10:30.000Z","date":"2017-06-28","kind":"sale","acquired":false,"shares":818,"price":60.47,"value":49464.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934."}],"balance_after":2128,"source":{"system":"sec-edgar","filing":"0001127602-17-022382","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760217022382/form4.xml","form_type":"4"}},{"id":4334544,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2017-05-03T16:27:39.000Z","date":"2017-05-02","kind":"tax_withholding","acquired":false,"shares":99,"price":57.48,"value":5690.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":2946,"source":{"system":"sec-edgar","filing":"0001127602-17-016620","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760217016620/form4.xml","form_type":"4"}},{"id":4371245,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-03-27T16:33:07.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":11062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in three equal annual installments beginning on February 14, 2018."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."}],"balance_after":11062,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":11062},"source":{"system":"sec-edgar","filing":"0001127602-17-012958","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760217012958/form4a.xml","form_type":"4/A","original_submission_date":"2017-02-16"}},{"id":4402372,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2017-03-03T16:15:10.000Z","date":"2017-03-02","kind":"tax_withholding","acquired":false,"shares":113,"price":52.81,"value":5967.53,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":3045,"source":{"system":"sec-edgar","filing":"0001127602-17-010129","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760217010129/form4.xml","form_type":"4"}},{"id":4408214,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-03-02T16:10:38.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":7030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests in full on the third anniversary of the date of grant."}],"balance_after":7030,"derivative":{"exercise_price":52.08,"expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":7030},"source":{"system":"sec-edgar","filing":"0001127602-17-009677","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760217009677/form4.xml","form_type":"4"}},{"id":4408213,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2017-03-02T16:10:38.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":211,"price":47.76,"value":10077.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":3158,"source":{"system":"sec-edgar","filing":"0001127602-17-009677","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760217009677/form4.xml","form_type":"4"}},{"id":4408212,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2017-03-02T16:10:38.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":3360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes restricted stock units granted by Bioverativ Inc. (\"Bioverativ\") to the reporting person as a result of the conversion of existing Biogen Inc. (\"Biogen\") restricted stock units held by the reporting person prior to the spin-off of Bioverativ from Biogen on February 1, 2017 (\"Spin-Off\"), as set forth in an employee matters agreement entered into between Bioverativ and Biogen in connection with the Spin-Off. Restricted stock units that are unvested continue to vest on the dates of the original Biogen awards."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 9 shares acquired in a pro rata distribution by Biogen in connection with the Spin-Off."}],"balance_after":3369,"source":{"system":"sec-edgar","filing":"0001127602-17-009677","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760217009677/form4.xml","form_type":"4"}},{"id":4441903,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-02-16T16:42:01.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":11043,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests in three equal annual installments beginning on February 14, 2018."}],"balance_after":11043,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":11043},"source":{"system":"sec-edgar","filing":"0001127602-17-006625","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760217006625/form4.xml","form_type":"4"}},{"id":4441902,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":31279,"kind":"person","name":"Duvall Diantha","position":1,"cik":"0001696784","reported_name":"Duvall Diantha","relationship":{"officer":true,"officer_title":"Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2017-02-16T16:42:01.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":4170,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."}],"balance_after":4170,"derivative":{"underlying":"Common Stock","underlying_shares":4170},"source":{"system":"sec-edgar","filing":"0001127602-17-006625","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681689/000112760217006625/form4.xml","form_type":"4"}}]}